医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SYDNEY

TranScrip Partners, Reading UK, the rapidly growing, cutting-edge contract organisation today announced the appointment of a new Senior Partner in Australia, Dr Glen Pater, a pharmaceutical physician with 25 years industry experience and a successful track record in drug development and life cycle management having been responsible for supporting several major Pacific Asia launches for big pharma. The appointment of a Senior Partner to the Australian office of TranScrip will therefore offer a substantial gateway to Asia. “This will allow us to better support our clients and their global programmes and add to the depth and breadth of our expertise in drug development and commercialisation”, said TranScrip’s Managing Partner, Dr Flic Gabbay.

TranScrip Partners supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies. TranScrip Partners challenges the traditional CRO model by offering to clients both top-level therapeutic expertise in overcoming the hurdles encountered from translational medicine to successful registration and market access and the staff to support the projects. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre and post-approval.

The unique “one-stop shop”, character of its organisational model, offers an innovative solution to managing the ever increasing costs of fixed overheads in Pharmaceutical R&D.

—ENDS—–

TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers that do, and doers who think strategically.

Working for more than 80 companies across four continents, TranScrip challenges the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.

Photograph is available on request.